Alaunos Therapeutics Inc. is a clinical-stage oncology-focused cell therapy company. It focused on developing T-cell receptor therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform. Alaunos Therapeutics Inc., formerly known as Ziopharm Oncology Inc., is based in HOUSTON.
Info & Links
CEO
Dale Curtis Hogue
Headquarters
2617 BISSONNET ST,SUITE 225 HOUSTON, TX 77005, UNITED STATES
Alaunos Therapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
2.68M
Enterprise Value
999.10K
Enterprise Value/EBITDA(ttm)
-0.08
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
0.95
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
25.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
-7056.25%
Return on Equity(ttm)
-267.77%
Return on Invested Capital(ttm)
-230.73%
Return on Assets(ttm)
-209.18%
Income Statement
Revenue(ttm)
6.00K
Revenue Per Share(ttm)
0.00
Gross Profit(ttm)
6.00K
EBITDA(ttm)3
-11.76M
Net Income Available to Common(ttm)
-11.78M
Diluted EPS(ttm)
--
Share Statistics
Beta (5Y Monthly)
-0.40
52-Week Change
-88.50%
S&P 500 52-Week Change
18.16%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
1.60M
Dividend Yield
0.00%
Float4
1.52M
% Held by Insiders
5.11%
% Held by Institutions
27.72%
Balance Sheet
Total Cash(mrq)
1.68M
Total Cash Per Share(mrq)
1.05
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
4.30%
Quick Ratio(mrq)
4.30%
Book Value Per Share(mrq)
1.70
Cash Flow
Operating Cash Flow Per Share(ytd)
-2.74
Free Cash Flow(ytd)
-4.38M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.